Catalyst Oncology

  Alimta, the first drug developed for maintenance therapy of metastatic lung cancer has been approved by US Food and Drug Administration (FDA). Lung Cancer patients, who are on remission after chemotherapy treatment, undergo maintenance therapy to prevent the disease from reviving and spreading. This happens when the cancer cells multiplies in the body. The new drug, Alimta, interfere in the metabolic process dependent on B-vitamin folate for cell reproduction. Richard Pazdur, M.D., Direct

Go here to see the original: 
Maintenance Drug Therapy for Advanced Lung Cancer receives FDA Approval